Treats noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly…. Sold as Rezdiffra. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Resmetirom (sold as Rezdiffra), first approved Mar 14, 2024, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Rezdiffra | Part D | $476M | +589% | 17,592 |
| Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom TherapyMetabolic Dysfunction-steatohepatitis (MASH) · Radnet Management, Inc. | — | Not yet recruiting | Oct 6, 2026 |
| Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisMASH - Metabolic Dysfunction-Associated Steatohepatitis · Madrigal Pharmaceuticals, Inc. | Phase 4 | Recruiting | Sep 29, 2026 |
| Resmetirom in Patients With MASH and HFpEFMASH - Metabolic Dysfunction-Associated Steatohepatitis, Heart Failure With Preserved Ejection Fraction (HFPEF) · Madrigal Pharmaceuticals, Inc. | Phase 1 | Recruiting | Sep 21, 2026 |
| Study of Resmetirom in Children and Adolescents With MASHMASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis · Madrigal Pharmaceuticals, Inc. | Phase 2 | Recruiting | Aug 13, 2026 |
| Nutrition Intervention Combined With Resmetirom for MASHMetabolic Dysfunction-Associated Steatohepatitis (MASH) · City University of New York | Phase 4 | Not yet recruiting | Jul 2, 2026 |
| Rezdiffra Pregnancy and Lactation RegistryMASH - Metabolic Dysfunction-Associated Steatohepatitis · Madrigal Pharmaceuticals, Inc. | — | Recruiting | Apr 21, 2026 |
| Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHMASH - Metabolic Dysfunction-Associated Steatohepatitis · Madrigal Pharmaceuticals, Inc. | Phase 2 | Recruiting | Jan 13, 2026 |
| Resmiterom Efficacy & Safety in Patients With MASHMASH - Metabolic Dysfunction-Associated Steatohepatitis · Nabiqasim Industries (Pvt) Ltd | Phase 4 | Recruiting | Nov 25, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
